© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2011
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Cholesterol Drug Statin May Improve Standard Hep C Treatment Efficacy

Medications sometimes prescribed to help manage high cholesterol levels also show promise as add-on treatments for hepatitis C, according to s...

Boceprevir Effective in Advanced Fibrosis or Cirrhosis

Merck’s HCV protease inhibitor boceprevir can be used safely and effective in people living with hepatitis C virus (HCV) with advanced...

Pharmasset’s Two-Drug Non-Interferon Combo Packs Quick Hep C Punch

A combination of two experimental once-a-day drugs active against the hepatitis C virus (HCV) is showing excellent potential, without the addi...

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

New Interferon Boosts Efficacy, Reduces Side Effect Risk

An experimental version of pegylated interferon, Peg-Interferon lambda, combined with ribavirin (RBV) appears to be more effective with...

Breakthrough: Non-Interferon/Ribavirin Regimen Can Cure Hep C

In what is being heralded as a hepatitis C virus (HCV) treatment research breakthrough, a clinical trial evaluating two oral medications being...

Cyclophilin Inhibitor Alisporivir Shows Promise in Phase II Hep C Study

Alisporivir, a once-daily drug at the forefront of a new class of hepatitis C virus (HCV) compounds known as cyclophilin inhibitors, significa...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

Once-Daily HCV Protease Inhibitor Meets Efficacy and Safety Goals in Phase II Studies

BI 201335, Boehringer Ingelheim’s experimental hepatitis C virus (HCV) protease inhibitor that may allow for once-a-day dosing, is show...

Telaprevir Improves Viral Cure Rates After Previous Treatment Failure

People living with hepatitis C virus (HCV) whose earlier treatment was unsuccessful are more likely to achieve a sustained virologic response...
Advertisement
Treatment News
Newsfeed
Features
Ask Hep